FROM APRIL to SEPTEMBER 2024 – VIRTUALLY by eScientiq, Inc.
Chronic Lymphocytic Leukemia
CLL Educational Program
Webinar 3 – June 21st 2024 at 3pm ET
Virtually by Live Streaming
The current landscape for CLL involves the use of new targeted therapies that offer increased efficacy and better tolerance compared to the primary chemotherapy treatments. Over the past decade, the clinical utilization of BTK inhibitors (BTKis) for treating B-cell malignancies, particularly CLL, has experienced significant growth, reshaping the therapeutic landscape. This event will deepen the understanding about the difference between covalent and non-covalent BTKis; mechanism of BTKi resistance; coping with the resistance; management of CLL patients; managing side effects of BTKis; choosing between different BTKis; clinical trials and results; and diagnosis and treatment of Richter Syndrome.
SPEAKER for Webinar 3
Dr. Varsha Gandhi
Dr. Gandhi is a Professor in Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. She received her PhD in Biochemistry from Delhi University, India in 1981. Her clinical experiences remind her that cancer is the most complex and daunting problem of our times, one that may not be cured by this generation. She educates the next generation of scientists by teaching them the fundamentals of cancer therapeutics and by supervising them as they test these agents in the laboratory and apply them in the clinic. She strives to provide students the tools to test their hypotheses and the critical thinking skills to generate many more. She motivates the researchers to be optimistic and to tackle the disease in the hope of curing it.
Dr. Gandhi is a Professor in Department of Experimental Therapeutics, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. She received her PhD in Biochemistry from Delhi University, India in 1981. Her clinical experiences remind her that cancer is the most complex and daunting problem of our times, one that may not be cured by this generation. She educates the next generation of scientists by teaching them the fundamentals of cancer therapeutics and by supervising them as they test these agents in the laboratory and apply them in the clinic. She strives to provide students the tools to test their hypotheses and the critical thinking skills to generate many more. She motivates the researchers to be optimistic and to tackle the disease in the hope of curing it.
